Introduction
============

The human T-cell leukemia virus type 1 (HTLV-1) was the first pathogenic retrovirus identified in human ([@B83]). It is estimated that 10--15 million individuals are infected with HTLV-1 around the world, with endemic areas in the Caribbean, southern Japan, Central and South America, Iran, Melanesia, and sub-Saharan Africa ([@B116]; [@B35]). While the vast majority of HTLV-1-infected individuals remain clinically asymptomatic, around 5% of them will develop a highly aggressive T-cell malignancy, termed adult T-cell leukemia/lymphoma (ATL) ([@B82]; [@B69]). ATL presents four distinct clinical stages ranging from smoldering to acute leukemia. It generally occurs in individuals infected around the time of birth eventually and it develops only after prolonged incubation periods ranging from 20 to 60 years ([@B84]). Although several studies have reported that the proviral DNA load is a critical factor for promoting disease progression in infected individuals ([@B98]; [@B53]; [@B140]), 30 years after its characterization in T-lymphocytes from leukemic patients, it is still not fully understood how HTLV-1 transforms human CD4+ T cells in a stepwise fashion. The current view is that pleiotropic functions of the HTLV-1 viral transcriptional transactivator Tax ([@B100]; [@B60]), such as deregulation of the signaling pathways AP-1 pathway ([@B32]) and NF-kB ([@B107]; [@B101]; [@B18]), and inactivation of tumor suppressors ([@B118]) are promitotic events, which drive CD4+ T-cell proliferation during the preleukemic stage ([@B82]). Paradoxically, fresh ATL cells lack Tax expression, due to genetic and epigenetic modifications in the HTLV-1 provirus ([@B119]; [@B66]). In contrast, HTLV-1 basic leucine-zipper factor (HBZ) mRNA which is encoded by the complementary strand of the HTLV-1 genome is expressed in all ATL cells ([@B88]; [@B81]). Recent studies have provided striking evidence for the important role played by of HBZ and the AP-1 pathway in HTLV-1 pathogenesis. In this review, we will limit our focus to the role of AP-1 activation by Tax and HBZ and discuss, in a non-exhaustive manner, how this activation relates to oncogenesis and inflammation.

The AP-1 Pathway, A Key Regulator of Cellular Transformation
============================================================

Activating protein-1 (AP-1) transcription factor has been linked to cancer and neoplastic transformation since the first cloning of *jun* and *fos* proto-oncogenes were cloned following their identification as cellular homologs of avian sarcoma virus 17 (ASV 17)-encoded oncogenes *vjun* and *vfos* 30 years ago ([@B23]). AP-1 is composed of 18 dimeric complexes which included members of four families of DNA-binding proteins: Jun family (c-Jun, JunB, v-Jun, JunD), Fos family (c-Fos, FosB, Fra-1, and Fra-2,) ATF/cyclic AMP-responsive element-binding (CREB) (activating transcription factor: ATF1--4, ATF-6, b-ATF, ATFx), and Maf family (musculoaponeurotic fibrosarcoma c-Maf, MafA, MafB, MafG/F/K, and Nrl) ([@B29]; [@B89]; [@B44]; **Figure [1](#F1){ref-type="fig"}**). Transcriptional activity of AP-1 is regulated by a wide array of cellular stimuli including growth factors, bacterial and viral infection, cytokines, UV radiation, and cellular stress ([@B29]; [@B89]; [@B44]; **Figure [1](#F1){ref-type="fig"}**). These transcription factors have critical functions in wide variety of cellular processes, including inflammation, proliferation, differentiation, and apoptosis ([@B29]; [@B89]; [@B44]). The activity of the different AP-1 dimer also depends on the cell type and its differentiation state. In response to external stimuli, MAPK activity increases and regulates both the abundance and transactivating capacities of Jun, Fos, and ATF (**Figure [2](#F2){ref-type="fig"}**). MAPKs are a serine/threonine kinase superfamily that comprises extracellular signal-regulated kinases (ERK), c-Jun NH2-terminal kinases (JNK), p38, and c-Fos-regulating kinases (FRK) ([@B17]; [@B63]; [@B117]). The regulation of AP-1 is complex and occurs at multiple levels, ranging from dimer composition, to transcriptional and post-translational events, and to specific interactions between AP-1 proteins and other transcription cofactors (**Figure [2](#F2){ref-type="fig"}**).

![Schematical presentation of the structure of AP-1 proteins. Activator protein 1 (AP-1) proteins include the JUN, FOS, activating transcription factor (ATF), and musculoaponeurotic fibrosarcoma (MAF) protein families, which can form homodimers and heterodimers through their leucine-zipper domains. The AP-1 proteins exhibit several domains, including the bZIP domain (leucine zipper plus basic domain), transactivation domains, and docking sites for several kinases, such as JNK or ERK. These kinases modulate the activity of those transcription factors by phosphorylation of serine and threonine residues.](fmicb-08-02686-g001){#F1}

![Transcriptional and post-translational activation of AP-1. AP-1 activity is stimulated by external stimuli like growth factors or inflammatory cytokines and a complex network of kinase such as mitogen-activated protein kinases (MAPKs) of the extracellular-signal regulated kinase (ERK), p38, and JUN amino-terminal kinase (JNK) families. Posttranslational phosphorylation by various kinases regulates AP-1 activity, which includes its transactivating potential, DNA-binding capacity, and the stability of AP-1 components. GSK-3β, glycogen synthase kinase-3β; MAPKK, MAPK kinase; RSK2, ribosomal S6 kinase 2; TCF, ternary complex factor; SRE, serum-response element; TRE, TPA-responsive element; CRE, cAMP-response element; SIE, Sis-inducible element.](fmicb-08-02686-g002){#F2}

AP-1 Transcriptional Regulation
-------------------------------

Activating protein-1 activity is modulated through its dimer composition which is determined by the differential expression of Jun, Fos, ATF, and Maf families (**Figure [1](#F1){ref-type="fig"}**) and through the sequence of the AP-1 DNA-binding sites (**Table [1](#T1){ref-type="table"}**). The abundance of the subunits can be controlled either via the regulation of the synthesis and stability of respective mRNAs or via the regulation of protein stability (for example, stimulus-dependent degradation via the ubiquitin pathway) ([@B92]). Most of the genes that encode AP-1 subunits behave as "immediate-early" genes. Indeed, they are rapidly but transiently transcribed in response to extracellular stimuli, such as growth factor ([@B108]; [@B65]) and cellular stress ([@B6]; [@B144]; **Figure [2](#F2){ref-type="fig"}**). Among these, the transcriptional regulation of *c-jun* and *c-fos* is well studied and characterized ([@B1]). The transcription of *c-fos* is induced in response to a diverse spectrum of extracellular stimuli and its promoter is composed of several transcription factor-binding sites, such as a cAMP-response element (CRE), which can drive transcriptional activation in response to elevation of intracellular Ca^2+^ or cAMP concentrations under stimulation from neurotransmitters and polypeptide hormones (**Figure [2](#F2){ref-type="fig"}**; [@B76]; [@B17]; [@B122]). It also contains a serum-response element (SRE), which can drive transcription in response to growth factors, cytokines, UV irradiation, and other stimuli. SRE is recognized by a dimer composed of serum-response factor (SRF) and Elk-1, the major component of ternary complex factor (TCF) in human cells ([@B76]; [@B17]; [@B122]; **Figure [2](#F2){ref-type="fig"}**). The third major element of c-Fos promoter is the v-Sis-inducible element (SIE) ([@B129]). SIE is mostly recognized by homodimers and heterodimers of STAT1 and STAT3, two members of the signal transducers and activators of transcription (STAT) family ([@B109]). Tyrosine phosphorylation of these factors in the cytoplasm is mediated by janus kinase/tyrosine kinase (JAK/TYKs) and drives their dimerization. The dimerized factor can then translocates to the nucleus, binds the SIE, and participates in promoter activation. Finally, the c-Fos promoter also contains a 12-*O*-tetradecanoyl-phorbol-13-acetate-response element (TRE) (**Figure [2](#F2){ref-type="fig"}**; [@B76]; [@B17]; [@B122]).

###### 

The different AP-1-binding sites.

            AP-1-binding sequence
  --------- -----------------------
  TRE       TGACTCA
  MAREI     TGCTGACTCAGCA
  CRE       TGACGTCA
  MARE II   TGCTGACGTCAGCA
  ARE       a/gtGACnnnGC

The main DNA response element is the TPA-responsive element (TRE), but different dimers preferentially bind to elements such as the cAMP-response element (CRE), the MAF-recognition elements (MAREs), and the antioxidant-response elements (AREs)

.

The *c-jun* promoter is simpler, being mostly induced through the TRE element that preferentially binds c-Jun/ATF2 heterodimers (**Figure [2](#F2){ref-type="fig"}**; [@B124]). Despite its inducible expression, most cell types prior to their stimulation contain basal levels of c-Jun protein. Like the *c-fos* SRE, the *c-jun* TRE is constitutively occupied *in vivo* ([@B124]). Thus, the expression of more than one AP-1 component is under positive and negative AP-1 (auto-)regulation. For example, *c-jun* and *atf3* promoters can be activated by c-Jun/ATF2 and/or ATF2/ATF2 via TRE-binding sites, whereas the *atf3* promoter is inhibited by ATF3 ([@B5]; [@B40]; [@B124]). The *c-jun* promoter can be inhibited by JunB, c-Jun itself, and c-Fos. This feedback control allows fine-tuned regulation of AP-1 heterodimer activity over longer periods of time ([@B20]).

Post-transcriptional Regulation of AP-1 Transcription Factors
-------------------------------------------------------------

Phosphorylation of AP-1 components modulates the dimers transcriptional activities ([@B64]). Serum and growth factors stimulation induces AP-1 by activating the ERK which then directly phosphorylate c-Jun, Fra-1, and Fra-2 (**Figure [2](#F2){ref-type="fig"}**). While phosphorylation of c-Jun by ERK on one serine located next to the C-terminal DNA-binding domain inhibits c-Jun DNA-binding activity, phosphorylation of Fra-1 and Fra-2 enhances their DNA binding in conjunction with c-Jun ([@B135]; [@B103]).

The induction of AP-1 by pro-inflammatory cytokines and genotoxic stress is mostly mediated by the JNK and p38MAPK pathways ([@B19]; **Figure [2](#F2){ref-type="fig"}**). Once activated, JNKs translocate to the nucleus, where they phosphorylate c-Jun on Ser 63/73 and Thr 91/93 and thereby potentiates its ability to activate transcription upon homodimerization or a heterodimerization with c-Fos ([@B135]; [@B25]; [@B103]). The molecular mechanisms underlying the capacity of JNK to control c-Jun activity involve the modulation of interactions with histone deacetylase complexes, sub-nuclear localization of AP-1 proteins, and related factors required for c-Jun-dependent activity. JNKs also phosphorylate ATF2 on Thr69/71 and potentiate its activity after heterodimerization with c-Jun, leading to its binding to divergent AP-1 sites in the *c-jun* promoter ([@B124]; [@B112]). Transactivation by ATF2 is also potentiated by binding of retinoblastoma (Rb) or E1A, to the DNA-bound ATF2 dimer ([@B75]). Both E1A and Rb act in concert with phosphorylation of ATF2. Although E1A induces c-jun transcription ([@B124]), it concomitantly represses AP-1 activity through competition for CREB-binding protein (CBP) in a similar manner to the competitive effect of E1A binding on p300 ([@B97]; [@B7]).

The contribution of p38 to AP-1 induction can be mediated by the direct phosphorylation and activation of ATF2 and TCFs (**Figure [2](#F2){ref-type="fig"}**; [@B87]; [@B134]). The PI3K/AKT pathway is activated in response to cytokine receptors and T-cell receptor activation in normal T cells. Akt is a serine/threonine protein kinase activated by PI3K through phosphorylation of Ser473, which acts as a regulator of cell survival and proliferation ([@B132]). In addition, glycogen synthase kinase-3 (GSK3), an effector kinase of the PI3K pathway, has the capacity to negatively regulate AP-1 transcriptional activity ([@B70]; [@B132]). GSK3 is a ubiquitously expressed serine/threonine kinase normally active in unstimulated cells. Upon stimulation by growth factors, GSK3 is phosphorylated at Ser9 and Ser21 (for GSK3β and GSK3a, respectively) by Akt and other kinases of the AGC family (protein kinase A, protein kinase G, protein kinase C) thus leading to an important decrease of its activity ([@B70]; [@B127]). GSK3 activity is controlled mainly through the PI3K/AKT pathway upon AKT phosphorylation on Ser473 ([@B70]). This complex network of signaling pathways reveals that a particular stimulus can evoke a specific "spectrum" of AP-1 activity and thereby activate and/or repress distinct subset of AP-1-targetted genes.

The Janus (Dual) Role of AP-1 in Cancer Development
---------------------------------------------------

A large amount of studies have shown that AP-1 components play an important role in oncogenesis. *c-jun* and *c-fos* were first identified as retrovirus-activated genes with oncogenic potential in avian and mammalian cells ([@B1]; [@B128]). Chronic exposure to carcinogens can promote tumorigenesis through the activation of a wide array of signaling pathways, ranging from inflammatory to pro-proliferative and survival pathways. Furthermore, environmental or dietary carcinogens have been shown to induce increased AP1 activity ([@B1]; [@B128]).

Many human cancers exhibit overexpression of Jun family members ([@B95]; [@B73]; [@B67]). Consistent with the idea that c-Jun can promote tumorigenicity, overexpression of this transcription factor is observed in some of the more aggressive CD30-positive lymphomas ([@B26]; [@B79]). In breast cancer, alteration of RB, VEGF, and EGFR pathways has been shown to induce c-Jun overexpression ([@B67]). Interestingly, increased c-Fos expression is associated with poor clinical outcome in osteosarcoma and endometrial carcinoma, while loss of c-Fos expression is associated with tumor progression and adverse outcome in ovarian carcinoma and gastric carcinoma ([@B122]). On the other side, Fra-1 overexpression is associated with the development of thyroid, breast, lung, brain, nasopharyngeal, esophageal, endometrial, prostate, and colon carcinomas, along with glioblastomas and mesotheliomas ([@B122]; [@B141]). The studies are strongly suggesting that the role of Fos family in tumors development depends on the tissue of origin.

Several studies have shown that AP-1 activity is crucial for tumorigenesis, as its inhibition by dominant-negative c-Jun mutants or AP-1 decoys strongly inhibits the growth of various tumor cell lines both *in vitro* and *in vivo* ([@B6]; [@B61]; [@B27]; [@B67]). These studies have also led to the identification of AP1 target genes involved in carcinogenesis ([@B29]; [@B75]; [@B94]). In addition, chronic exposure to environmental and dietary carcinogens such as cigarette smoke or nicotine or ethanol, activates AP1 activity in mouse brain or epithelial cell lines or neuroblastoma cells ([@B31]; [@B58]; [@B78]). Interestingly, increase in AP1 activity has been also reported in drug-resistant cancer, suggesting that some chemotherapeutic agents can elicit AP1 activation and favor tumor cell survival by making them refractory to long-term treatments ([@B77]; [@B30]; [@B74]).

Overexpression of Jun and Fos proteins can also suppress tumor formation ([@B29]; [@B45]; [@B111]), thus revealing the double-edged activity of AP-1 transcription factors. These dual properties depend on the genetic background of the tumor, its differentiation state, and tumor stage ([@B29]; [@B45]; [@B111]). Several studies have shown that increased AP-1 activity can lead to apoptosis in human tumor cells but it can also antagonize apoptosis in specific cell types, such as liver tumors ([@B29]; [@B45]; [@B111]). This dual effect of AP-1 on apoptosis can be further exemplified. Indeed, increased c-Jun activity promotes apoptosis in neuronal cells *in vitro* ([@B42]). When the activation of c-Jun is impaired, either in Jnk3-null or JunAA mice, which express a c-Jun insensitive to JNK-mediated activation, neurons are protected from apoptosis ([@B11]). In contrast, c-Jun is required for the survival of fetal hepatocytes, which undergo apoptosis in c-Jun-deficient mouse embryos ([@B28]; [@B43]). The cell-specific consequence of AP-1 activity over apoptosis is likely due to its differential regulation of pro-apoptotic and anti-apoptotic target genes. In neurons, c-Jun regulates the expression of Bim, a pro-apoptotic Bcl-2 family member that is crucial for neuronal apoptosis. While in T cells, c-Jun regulates the expression of Fas ligand (FasL), which upon binding to the Fas receptor triggers apoptosis ([@B29]; [@B45]; [@B111]). Bcl-2 family members are also part of the list of anti-apoptotic targets that are regulated by AP-1 ([@B68]). In T cells, Jun members exert a protective signal through the induction of Bcl-3, while in myeloid cells, inactivation of JunB leads to reduced apoptosis with increased expression of the anti-apoptotic Bcl-2 gene ([@B72]; [@B117]; [@B68]) have shown that hepatocytes deficient for c-Jun or JunD are highly sensitive to tumor necrosis factor-α-induced apoptosis, thus suggesting that c-Jun and JunD might regulate genes that protect cells from TNF-α-induced-cell death. Those studies have demonstrated that depending on the type of extracellular stimuli and on the cellular context, activation of AP-1 can have a different outcome on the cell fate. Therefore, the role and function of AP-1 in cancer development should be examined within the context of a complex network of simultaneously triggered signaling pathways.

Regulation of AP-1 During HTLV-1 Infection
==========================================

Human T-cell leukemia virus type 1 can infect a variety of cell types *in vivo*, including T cells, B cells, and macrophages ([@B59]; [@B102]; [@B38]; [@B106]). The HTLV-1 provirus is detected mainly in CD4+ T cells and to lesser extent in CD8+ T cells ([@B105]; [@B51]; [@B86]). This asymmetry in detection may be caused by recruitment of CD4+ T cells and induction of their proliferation following HTLV-1 infection in contrast to a delayed cell death in CD8+ T cells ([@B115]; [@B4]). A subset of HTLV-1-infected individuals will develop ATL after an extended period of time ([@B82]; [@B62]). Infected cells, however, must initiate proliferation and evade apoptosis as a prelude to immortalization and transformation. Virally encoded oncogenic proteins are known to dysregulate various cellular pathways or processes through the regulation of the activity of target proteins. HTLV-1 transforms T cells via its transactivator Tax, which interferes with pathways regulating cell growth control through activation of various cellular transcription factors (NF-κB, E2F, and AP-1) ([@B32]; [@B101]; [@B60]) and inactivation of p53 ([@B118]). Since AP-1 has been implicated in transformation of T cells, it has been hypothesized that inappropriate activation of AP-1 could contribute to the dysregulated phenotype of HTLV-1-infected cells or to the development of ATL. Indeed, ATL leukemic cells exhibit increased levels of mRNAs encoding JunD and Fra-2 ([@B93]; [@B120]) and high levels of AP-1-binding activity ([@B32]; [@B52]), with in addition, AP-1, more specifically c-Jun/c-Fos heterocomplex, induces HTLV-1 promoter activity and thus participates in HTLV-1 basal transcription ([@B55]).

Activation of the AP-1 Pathway by Tax during Acute HTLV-1 Infection
-------------------------------------------------------------------

The phosphoprotein Tax is encoded within the pX region of HTLV-1 genome and is a viral regulatory protein. This protein mainly localizes to the nucleus and is a well-known trans-activator of the HTLV-1 long terminal repeat (LTR) operating through three 21-bp repeats called Tax-responsive elements (TxREs) ([@B85]; [@B37]). Its pleiotropic properties confer a pivotal role for Tax toward viral pathogenicity and immortalization/transformation of infected cells, causing the onset of HTLV-1-associated diseases ([@B36]; [@B100]). Indeed, the protein is sufficient for immortalizing primary human T cells and rodent fibroblasts as well as inducing tumors in nude mice inoculated with Tax-transformed cells ([@B37]). Furthermore, Tax interferes with important functions, leading to cell cycle dysregulation and promoting *in vivo* clonal expansion ([@B36]; [@B100]). Moreover, Tax can alter the expression of cellular proteins involved in cell growth and proliferation such as cytokines ([@B37]; [@B83]). Importantly, this trans-acting factor also acts as a transcriptional regulator of gene expression by recruiting or modifying the activity of cellular transcription factors (such as CREB protein, SRF, NF-κB, and notably AP-1) through direct or indirect interactions ([@B37]; [@B83]).

Tax activates the transcription of cellular genes by activating AP-1 DNA binding to promoter elements in T cells ([@B32]; [@B52]; **Figure [3](#F3){ref-type="fig"}**). Thus, activation of AP-1 by Tax is thought to contribute to the deregulated phenotypes and leukemogenesis of T cells infected with HTLV-I. Among these factors, c-Fos, Fra-1, c-Jun, JunB, and JunD genes have been shown to be activated by Tax at the transcriptional level ([@B32]; [@B52]; **Figure [3](#F3){ref-type="fig"}**). Interestingly, exogenous expression of Tax in Jurkat cells induced AP-1-dependent transcription of a reporter gene more efficiently than any combinations of AP-1 proteins ([@B32]; [@B52]). Thus, the well-known induction of expression of multiple Fos and Jun family members by Tax is known to be essential, but may not be sufficient, for the transcriptional activation of AP-1 sites mediated by Tax ([@B32]; [@B52]). Since DNA-binding activity and transcriptional activation of AP-1 are regulated at a post-translational level, Tax might be involved in this regulation ([@B32]; [@B52]). Tax contributes to the high activity of AP-1 in HTLV-1-infected cells through different mechanisms with intricate ramifications in cascade signaling (**Figure [3](#F3){ref-type="fig"}**). A constitutive activation of JNK had initially been reported in HTLV-1-infected cells, such as Tax-expressing MT-2 cells and Tax-ATL primary cells. Furthermore, this activity seemed to depend on the status of infection ([@B136]). Interestingly, Tax is responsible for the constitutive activation of PI3K/Akt by impairing the association between the catalytic (p110) and the regulatory subunit (p85) leading to Akt Ser ^473^ phosphorylation in HTLV-1-infected cell lines ([@B99]; **Figure [3](#F3){ref-type="fig"}**).

![Mechanisms of Tax activation of AP-1 pathway. Pathways upstream of AP-1 are normally activated in response to external stimuli whereas presence of Tax overrides this requirement. Indeed Tax is able to activate the Akt/PI3K pathway as well as the SRF pathways thus activating at the transcription of c-Fos, Fra-1, c-Jun, JunB, and JunD genes. By interacting with the JNK inhibitor G-protein pathway suppressor 2 (GPS2), Tax also participate to the exhibited highly activity of AP-1 in HTLV-1 infected cells through a constitutive activation of JNK ([@B57]). Interestingly, AP-1 proteins such as c-Jun and c-Fos activate the transcription through the 21 bp repeat in HTLV-1 LTR.](fmicb-08-02686-g003){#F3}

Pathways lying upstream of AP-1 are normally activated in response to external stimuli whereas Tax overrides this requirement (**Figure [3](#F3){ref-type="fig"}**). Additionally, the PI3K/Akt-AP-1 pathway had been involved in survival and is likely to be required for the immortalization of HTLV-1-infected cells ([@B56]). Indeed, Tax even in the absence of NF-κB signaling is able to activate the Akt/PI3K pathway, which upon inhibition by dominant-negative mutants for Akt or for c-Jun abolishes the proliferation of Tax-transfected cell lines as well as the transformed phenotype ([@B99]). AP-1 sites are Tax-inducible elements in different cellular genes, which promote cell proliferation and are associated with clinical characteristic features of ATL (**Figure [3](#F3){ref-type="fig"}**). Among target genes regulated by AP-1-binding sites, Tax activates growth-promoting cytokine genes, such as IL-2, IL-5, IL-13, as well as proinflammatory cytokines, such as IL-8 and TNF-a, and further induces the expression of immunosuppressors, like TGF-b1 and proenkephalin (PENK). This deregulation implies different combinations of dimerized AP-1 complex although they have not all been characterized as to their targeted promoters ([@B13]; [@B130]; [@B137]; [@B54]; [@B41]).

Tax does not always activate cellular promoters bearing AP-1-binding site (for example, the collagenase gene) ([@B41]). Rather, another mechanism, by which promoter could be regulated by Tax through AP1, is linked to the binding of Tax and c-Jun to an overlapping region corresponding to the KIX domain of CBP. This could induce a competition between these two proteins for CBP interaction and lead to the repression of c-Jun transcription activity by Tax ([@B126]; [@B125]). Although Tax induces the transactivation of the TGF-b1 promoter through AP-1 sites, Tax inhibits TGF-b1 signaling by reducing DNA-binding activity of Smad3 through a Smad3/c-Jun complex, which might be involved in the resistance of TGF-b1-induced growth inhibition observed in ATL cells, an important step in the pathogenesis of ATL ([@B8]). An opposite effect could be imputed to HBZ which could overcome the repressing effect of Tax on TGF-b1 signaling ([@B143]). Tax might not solely account for the constitutive activity of AP-1, since a high activity of AP-1 has been detected in primary Tax^-^ leukemia cells of ATL patients ([@B32]). These observations indicate that AP-1 is activated in HTLV-1-infected T cells through Tax-dependent and Tax-independent mechanisms.

Hijacking of the AP-1 Signaling Pathway by HBZ
----------------------------------------------

Within its antisense strand, HTLV-1 codes for a bZIP factor, which was appropriately named HBZ (HTLV-I bZIP factor) ([@B33]; [@B88]). HBZ can express under three isoforms: one unspliced form (usHBZ) and two alternatively spliced forms (HBZ-SP1 and HBZ-SP2) ([@B16]; [@B91]) with HBZ-SP1 (or sHBZ) being the most abundant spliced variant. sHBZ is a 31-kDa protein with an N-terminal transcriptional activation domain, a central domain involved in nuclear localization, and a C-terminal bZIP domain ([@B33]; [@B88]). Sequence comparison between HBZ bZIP region and several bZIP factors clearly indicates that HBZ possesses a c-Fos-like bZIP domain although its DNA-binding domain lacks the consensus amino acid sequence bb-bN--AA-b(C/S)R-bb thought to be critical for DNA binding. HBZ interacts with all the members of the Jun family (JunB, c-Jun, and JunD), and differently regulates the transcriptional properties of the Jun family ([@B10]; [@B49], [@B48]; [@B21]).

Sequestration of JunB and c-Jun in HBZ Nuclear Bodies Inhibits Their Transcriptional Activities
-----------------------------------------------------------------------------------------------

HTLV-1 basic leucine-zipper factor is a nuclear protein, which not only accumulates in specific nuclear bodies (called here HBZ-NBs) but is targeted to nucleoli ([@B49]). Using a fluorescence recovery after photobleaching approach (FRAP) and an EGFP-tagged-HBZ, [@B48] have observed that the deletion of its leucine-zipper domain altered the rate of nuclear flux of HBZ, suggesting that HBZ heterodimerization partners are involved in controlling its own nuclear trafficking. Indeed, HBZ modifies the localization of JunB and targets JunB to the HBZ-NBs. Moreover, the relocalization of JunB into HBZ-NBs inhibits its transcriptional activity ([@B48]; [@B21]; **Figure [4](#F4){ref-type="fig"}**).

![Differential effects of HBZ on the Jun family proteins. HBZ specifically interacted with all three members of the Jun Family (JunB, c-Jun, and JunD), but it regulates differently the transcriptional properties of the Jun family. HBZ dramatically suppressed c-Jun- and JunB-induced transcriptional activation from the AP-1 element by sequestering c-Jun and JunB into HBZ-NB and by decreasing the steady-state level of c-Jun and the stability of c-Jun protein in cells through a proteasome-dependent pathway. It is particularly interesting to note that HBZ has a different and opposite action on JunD expression. HBZ can stimulate the transcription of JunD and by nuclear retention of RPS25, HBZ allows the expression of an alternative isoform of JunD called ΔJunD. Furthermore, HBZ cooperates with JunD and sp1 to enhance transcription of the 3′-LTR and also the human telomerase reverse transcriptase gene (hTERT).](fmicb-08-02686-g004){#F4}

Although HBZ and c-Fos can both interact with c-Jun, they differ greatly in their abilities to activate transcription of AP-1-regulated genes. Indeed, the interaction of HBZ with c-Jun prevents this transcription factor from activating transcription of AP-1-dependent promoters by decreasing its DNA-binding activity ([@B21]). The generation of different c-Fos/HBZ chimeras by region swapping indicates that the HBZ DNA-binding motif has an important impact on the transcriptional activity of both transcription factors in the presence of c-Jun ([@B48]; [@B21]). Indeed, the mutant HBZ-mutMD/DBD, for which specific residues present in the MD and DBD regions of HBZ were substituted for corresponding amino acids of c-Fos, showed a significant *in vitro* affinity for the AP-1-binding site TRE but remained unable to stimulate promoter activity of the AP-1-dependent collagenase gene *in vivo*. Like JunB, c-Jun is also relocalized to HBZ-NBs in the presence of HBZ-mutMD/DBD, while this transcription factor is diffusely distributed throughout the nucleus in the presence of HBZ-H14F (a construction in which the bZIP domain of HBZ-mutMD/DBD was replaced by the corresponding ZIP domain of c-Fos), suggesting that HBZ- inhibits c-Jun DNA-binding capacity *in vivo* mainly by its sequestration to the HBZ-NBs ([@B48]; [@B21]) (**Figure [4](#F4){ref-type="fig"}** blue circle).

HBZ Promotes the Proteosomal Degradation of c-Jun
-------------------------------------------------

HTLV-1 basic leucine-zipper factor can also decrease the stability of c-Jun in cells and promote its degradation ([@B80]). Indeed, in cells transfected with usHBZ, [@B80] observed that treatment with proteasome inhibitors but not with calpain inhibitors prevented the reduction in the steady state of c-Jun, suggesting that this HBZ-mediated reduction in c-Jun abundance could also occur through a proteasome-dependent pathway. It has also been suggested by [@B50] that HBZ could act as a tethering factor between the 26S proteasome and c-Jun (**Figure [4](#F4){ref-type="fig"}**). However, c-Jun is less degraded by sHBZ (also called HBZ-SP1) than by usHBZ ([@B50]) and it remains unclear how both isoforms of HBZ could inhibit c-Jun through two different mechanisms.

HBZ Activates the Transcriptional Activity of JunD
--------------------------------------------------

It is particularly interesting to note that HBZ has a different and opposite effects on c-Jun- and JunD-dependent transcription. Indeed, these two proteins belong to the same family of transcription factors, but they are very different proteins. In JunD expressing cells, HBZ is diffusely distributed throughout the nucleoplasm, while no HBZ-NBs are formed ([@B48]). Interestingly, JunD is the only Jun family member, which can be activated by HBZ ([@B121]; [@B71]). It is worth noting that the presence of the EQERRE motif in HBZ modulates JunD activity ([@B49]). When the HBZ DNA-binding motif is substituted by the c-Fos modulatory domain, HBZ is no longer able to stimulate the transcriptional activity of JunD, although no alteration in the JunD DNA-binding activity is observed ([@B49]). It is important to note that the abundance and activity of JunD increase in freshly isolated ATL cells concomitantly with an increase of HBZ expression ([@B93]; [@B120]). These observations suggest that HBZ modulates its own expression through a positive-feedback loop in resting cells that involves cooperation with JunD (**Figure [4](#F4){ref-type="fig"}**). Indeed, in HTLV-1-infected cells, HBZ enhances expression of JunD, which leads to the association of JunD and HBZ to Sp-1 bound to the 3′′-LTR-containing antisense promoter and, ultimately, to the activation of *hbz* transcription ([@B34]).

In association with JunD and Sp-1, HBZ also activates the transcription of the human telomerase catalytic subunit gene (hTERT) ([@B71]). Telomerase, a ribonucleoprotein complex that extends telomeres which are essential for protecting chromosomal ends against end--end fusions or degradation ([@B22]; [@B15]; [@B110]). While mouse telomerase (mTERT) is activated in many normal tissues, human cells rarely spontaneously reactivate expression of the telomerase gene, as its expression is tightly regulated ([@B22]; [@B15]; [@B110]). However, 75--85% of cancer cells including ATL cells present an increase in telomerase expression and activity ([@B123]; [@B14]; [@B15]; [@B113]). Human telomerase is composed of a structural RNA component (hTERC), which contains an 11-base sequence complementary to the telomeric single-stranded overhang acting as a template for the synthesis of telomeric DNA. The other main component of the hTERT is its enzymatic reverse transcriptase subunit ([@B22]; [@B15]; [@B110]). Expression of *hTERT* is regulated mainly at the transcriptional level. The proximal 180 bp of the *hTERT* promoter, which does not contain any AP-1-binding site, is important for maintaining basal transcriptional activity and is thought to be the essential component for its regulation. Interestingly, [@B71] have observed an increase in hTERT transcripts in cells co-expressing HBZ and JunD. Chromatin immunoprecipitation (ChIP) assays revealed that HBZ/JunD heterodimers interact with Sp1 and that activation of hTERT transcription by this trimer is mediated through Sp-1-binding sites present in the core region of the *hTERT* promoter ([@B71]).

We recently uncovered an additional mechanism used by HBZ to turn JunD from a growth suppressor to a tumor promoter ([@B120]). *JunD* is an intronless gene and produces two predominant isoforms by alternative initiation of translation, a 39-kDa protein (JunD-FL) through initiation from the first AUG codon and a shorter, 34-kDa JunD protein (ΔJunD) through the use of the second in-frame AUG codon ([@B47]; [@B12]; [@B114]). Several studies indicated that JunD-FL and ΔJunD are differentially regulated through interactions with other nuclear proteins ([@B47]; [@B12]; [@B114]). For example, menin, the product of the tumor-suppressor MEN-1 gene, represses JunD-FL transcriptional activity by interacting through its first 48 amino acids ([@B2]; [@B138]). Loss of menin expression or lost the ability of menin to bind JunD confers JunD with growth-promoting capabilities ([@B3]). ΔJunD does not bind menin, and its transcriptional activity is unaffected by menin overexpression ([@B138]). In addition, JNK binds and activates JunD-FL more efficiently than ΔJunD, even though both JunD isoforms contain a JNK-docking domain and three JNK phosphorylation target sites. It is interesting to note that freshly isolated ATL cells and HBZ-expressing T lymphocytes express both JunD isoforms ([@B139]).

JunD mRNA contains a third functional out-of-frame ORF (uORFs) positioned between the ATG of JunD-FL and ATG of ΔJunD ([@B114]). Translation of downstream ORFs by uORF appears to be a common translational regulatory mechanism, as uORFs are present in two-third of mRNAs encoding oncoproteins and proteins that regulate important cellular processes. Alteration of protein expression levels by disruption or creation of uORF has been associated with the development of several human disease such as Alzheimer's disease, acute myeloid leukemia, and breast cancer ([@B114]; [@B145]; [@B133]; [@B9]). HBZ relieves uORF translational control by reducing the cellular abundance of RPS25, a ribosomal protein known to play a key role in several alternative translation mechanisms ([@B96]). Using an immortalized fibroblast cell line model, we found that ΔJunD exhibits growth-promoting and -transforming activities that are enhanced in presence of HBZ ([@B120]). In summary, it has been proposed that HBZ/JunD heterodimers induce down-regulation of lymphocyte activation and viral transcription to favor viral latency and persistence of the infected cells. Future studies will aim to clarify how HBZ/JunD and/or HBZ/ΔJunD coordinately drive cell fate toward cellular transformation.

Perspectives and Conclusion
===========================

Activating protein-1 family members have both overlapping and unique roles, and the transcriptional activity of the AP-1 dimer functions in a tissue-specific fashion ([@B111]). With respect to this important fact, recent studies have included the analysis of expression and/or activity of all Jun and Fos family members. Thus, it has been demonstrated that malignant transformation and tumor progression is accompanied by a cell-type-specific shift in AP-1 dimer composition ([@B128]; [@B104]; [@B65]; [@B122]; [@B112]; [@B29]; [@B89]; [@B44]; [@B111]). Those studies support a model, in which a shift in the expression pattern of the Fos family members is a crucial step in carcinogenesis and/or tumor progression ([@B122]; [@B89]). Indeed, while uninfected CD4+ T-lymphocytes express mainly c-Jun and c-Fos proteins, ATL-leukemic cells are expressing JunD and Fra-2 ([@B93]; [@B120]). Due to their lack of a trans-activating domain, it has been suggested that Fra-1 and Fra-2 might exert anti-tumor effect and inhibit tumor cell growth. Yet, recent studies point to a positive effect of Fra-1, and partly Fra-2, on tumor growth ([@B141]; [@B90]; [@B93]; [@B24]; [@B46]; [@B131]; [@B39]).

Indeed, gene substitution experiments in mice have shown that growth retardation and osteoporosis observed in c-Fos null-mice were rescued by Fra-1 overexpression, although Fra-1 failed to induce expression of c-Fos target genes, such as MMP13 and vimentin ([@B141]). This observation is in line with results obtained in various cancer cell types, in which Fra-1 alters the biological behavior of the cells without directly activating AP-1-responsive promoters ([@B142]; [@B141]). Surprisingly, in most of the clinical tumor samples analyzed so far, Fra-1 expression is lower than in normal cells, and the protein is poorly phosphorylated ([@B142]; [@B141]). These observations raised several interesting questions on the true role of Fra-1 in oncogenesis and tumor progression. Indeed, whether the low level Fra-1 expression is due to tumor heterogeneity and if expression Fra-1 in specific clones within the tumors have a similar effect to what is seen in experimental systems and contributes to local invasion and metastasis should be further studied. In contrast to the bulk of data available on the function of c-Fos and Fra-1 in carcinogenesis, far less is known on the role of other Fos family members (FosB, FosB2, deltaFosB2, and Fra-2), which are often found expressed in high levels in cancer tissues. Further study of the role of all Fos proteins in carcinogenesis will be of great importance.
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